Mylan Must Shell Out $18M To Sunovion In Xopenex Patent Suit
After a two-week trial, the jury rejected Mylan's contention that the Sunovion patents were invalid. It awarded Sunovion $17 million in lost profits stemming from Mylan's sales of generic Xopenex, known as levalbuterol hydrochloride, and awarded $1 million in royalties.
"While this is not a significant product for Mylan,...
To view the full article, register now.